Pub Date : 2024-10-17DOI: 10.1016/j.jhep.2024.10.010
Guanglin Xiao, Hong Ren
Section snippets
Financial support
This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University
Authors’ contributions
G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.
Declaration of Competing Interest
The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.
{"title":"Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B","authors":"Guanglin Xiao, Hong Ren","doi":"10.1016/j.jhep.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.010","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University</section></section><section><section><h2>Authors’ contributions</h2>G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-17DOI: 10.1016/j.jhep.2024.10.011
Henry Lik Yuen Chan
Section snippets
Financial support
none
Declaration of Competing Interest:
HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.
{"title":"Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure","authors":"Henry Lik Yuen Chan","doi":"10.1016/j.jhep.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.011","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>none</section></section><section><section><h2>Declaration of Competing Interest:</h2>HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel biomarkers predicting successful regeneration would likely improve patient selection for plasma exchange in acute liver failure","authors":"Oliver D. Tavabie, Varuna R. Aluvihare","doi":"10.1016/j.jhep.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.009","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributions</h2>Both authors conceptualised the manuscript. ODT composed the first draft. VRA made critical revisions</section></section><section><section><h2>Financial support</h2>Nil</section></section><section><section><h2>Conflicts of interest</h2>ODT have received consultancy fees from Chiesi. VRA has nil to declare</section></section><section><section><h2>Acknowledgements</h2>Nil</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/j.jhep.2024.06.041
{"title":"Two episodes of jaundice within 1 year in a teenager","authors":"","doi":"10.1016/j.jhep.2024.06.041","DOIUrl":"10.1016/j.jhep.2024.06.041","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/S0168-8278(24)02512-1
{"title":"JHEP at a Glance November 2024","authors":"","doi":"10.1016/S0168-8278(24)02512-1","DOIUrl":"10.1016/S0168-8278(24)02512-1","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/j.jhep.2024.06.015
{"title":"Granulomatous hepatitis, a mystery solved","authors":"","doi":"10.1016/j.jhep.2024.06.015","DOIUrl":"10.1016/j.jhep.2024.06.015","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolic dysfunction-associated steatohepatitis (MASH) is associated with more than a 10-fold increase in liver-related mortality. However, biomarkers predicting both MASH and mortality are missing. We developed a metabolome-derived prediction score for MASH and examined whether it predicts mortality in Chinese and European cohorts.
Methods
The MASH prediction score was developed using a multi-step machine learning strategy, based on 44 clinical parameters and 250 plasma metabolites measured by proton nuclear magnetic resonance (1H-NMR) in 311 Chinese adults undergoing a liver biopsy. External validation was conducted in a Finnish liver biopsy cohort (n=305). We investigated association of the score with all-cause and cause-specific mortality in the population-based Shanghai Changfeng Study (n=5,893) and the UK Biobank (n=111,673).
Results
A total of 24 clinical parameters and 194 1H-NMR metabolites were significantly associated with MASH in the Chinese liver biopsy cohort. The final MASH score included body mass index, aspartate transaminase, tyrosine, and the phospholipids-to-total lipids ratio in very-low density lipoprotein. The score identified patients with MASH with AUROCs of 0.87 (95% CI, 0.83-0.91) and 0.81 (95% CI, 0.75-0.87) in the Chinese and Finnish cohorts, with high negative predictive values. Participants with a high or intermediate risk of MASH based on the score had a markedly higher risk of MASLD-related mortality than those with a low risk in Chinese (HR, 23.19; 95%CI, 4.80-111.97) and European individuals (HR, 27.80; 95%CI, 15.08-51.26) after 7.4 and 12.6 years of follow-up. The MASH prediction score was superior to the FIB-4 index and the NAFLD Fibrosis Score in predicting MASLD-related mortality.
Conclusion
The metabolome-derived MASH prediction score accurately predicts risk of MASH and MASLD-related mortality in both Chinese and European individuals.
Impact and implications
Metabolic dysfunction-associated steatohepatitis (MASH) is associated with more than a 10-fold increase in liver-related death. However, biomarkers predicting not only MASH, but also death due to liver disease, are missing. We established a MASH prediction score based on 44 clinical parameters and 250 plasma metabolites using a machine learning strategy. This metabolome-derived MASH prediction score could accurately identify patients with MASH among both Chinese and Finnish individuals, and it was superior to the FIB-4 index and the NAFLD Fibrosis Score in predicting MASLD-related death in the general population. Thus, the new MASH prediction score is a useful tool for identifying individuals with a markedly increased risk of serious liver-related outcomes among at-risk and general populations.
{"title":"A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease","authors":"Qingxia Huang, Sami F. Qadri, Hua Bian, Xiaoxuan Yi, Chenhao Lin, Xinyu Yang, Xiaopeng Zhu, Huandong Lin, Hongmei Yan, Xinxia Chang, Xiaoyang Sun, Shuai Ma, Qi Wu, Hailuan Zeng, Xiqi Hu, Yan Zheng, Hannele Yki-Järvinen, Xin Gao, Huiru Tang, Mingfeng Xia","doi":"10.1016/j.jhep.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.015","url":null,"abstract":"<h3>Background</h3>Metabolic dysfunction-associated steatohepatitis (MASH) is associated with more than a 10-fold increase in liver-related mortality. However, biomarkers predicting both MASH and mortality are missing. We developed a metabolome-derived prediction score for MASH and examined whether it predicts mortality in Chinese and European cohorts.<h3>Methods</h3>The MASH prediction score was developed using a multi-step machine learning strategy, based on 44 clinical parameters and 250 plasma metabolites measured by proton nuclear magnetic resonance (<sup>1</sup>H-NMR) in 311 Chinese adults undergoing a liver biopsy. External validation was conducted in a Finnish liver biopsy cohort (n=305). We investigated association of the score with all-cause and cause-specific mortality in the population-based Shanghai Changfeng Study (n=5,893) and the UK Biobank (n=111,673).<h3>Results</h3>A total of 24 clinical parameters and 194 <sup>1</sup>H-NMR metabolites were significantly associated with MASH in the Chinese liver biopsy cohort. The final MASH score included body mass index, aspartate transaminase, tyrosine, and the phospholipids-to-total lipids ratio in very-low density lipoprotein. The score identified patients with MASH with AUROCs of 0.87 (95% CI, 0.83-0.91) and 0.81 (95% CI, 0.75-0.87) in the Chinese and Finnish cohorts, with high negative predictive values. Participants with a high or intermediate risk of MASH based on the score had a markedly higher risk of MASLD-related mortality than those with a low risk in Chinese (HR, 23.19; 95%CI, 4.80-111.97) and European individuals (HR, 27.80; 95%CI, 15.08-51.26) after 7.4 and 12.6 years of follow-up. The MASH prediction score was superior to the FIB-4 index and the NAFLD Fibrosis Score in predicting MASLD-related mortality.<h3>Conclusion</h3>The metabolome-derived MASH prediction score accurately predicts risk of MASH and MASLD-related mortality in both Chinese and European individuals.<h3>Impact and implications</h3>Metabolic dysfunction-associated steatohepatitis (MASH) is associated with more than a 10-fold increase in liver-related death. However, biomarkers predicting not only MASH, but also death due to liver disease, are missing. We established a MASH prediction score based on 44 clinical parameters and 250 plasma metabolites using a machine learning strategy. This metabolome-derived MASH prediction score could accurately identify patients with MASH among both Chinese and Finnish individuals, and it was superior to the FIB-4 index and the NAFLD Fibrosis Score in predicting MASLD-related death in the general population. Thus, the new MASH prediction score is a useful tool for identifying individuals with a markedly increased risk of serious liver-related outcomes among at-risk and general populations.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/j.jhep.2024.10.013
Terry Cheuk-Fung Yip, Nana Peng, Jimmy Che-To Lai
Section snippets
Financial support
None
Authors contributions
All authors were responsible for the study concept and design, interpretation of data, drafting and the critical revision of the manuscript for important intellectual content, and approved the final version of the article.
Declaration of Competing Interest
Jimmy Lai has served as an advisory committee member for Gilead Sciences and Boehringer Ingelheim, and a speaker for Gilead Sciences and Abbott. Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Nana Peng declares no competing interests.
{"title":"Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B – Reply to Di et al. and Huang et al.","authors":"Terry Cheuk-Fung Yip, Nana Peng, Jimmy Che-To Lai","doi":"10.1016/j.jhep.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.013","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Authors contributions</h2>All authors were responsible for the study concept and design, interpretation of data, drafting and the critical revision of the manuscript for important intellectual content, and approved the final version of the article.</section></section><section><section><h2>Declaration of Competing Interest</h2>Jimmy Lai has served as an advisory committee member for Gilead Sciences and Boehringer Ingelheim, and a speaker for Gilead Sciences and Abbott. Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Nana Peng declares no competing interests.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/j.jhep.2024.10.006
Jorge Martinez-Laso, Isabel Cervera, Milagros Muñoz, Inmaculada Casas, Ana Avellon
Section snippets
Financial support
this study was supported by CIBER of Epidemiology and Public Health (CIBERESP)
Authors contributions
Ana Avellón designed the study and was the principal investigator of the study. Jorge Martinez-Laso developed the HLA study and interpreted its results. Isabel Cervera and Milagros Muñoz provided technical assistance. Inmaculada Casas was responsible of storage of total blood samples. Jorge Martinez-Laso and Ana Avellón wrote the manuscript.
{"title":"Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease?","authors":"Jorge Martinez-Laso, Isabel Cervera, Milagros Muñoz, Inmaculada Casas, Ana Avellon","doi":"10.1016/j.jhep.2024.10.006","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.006","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>this study was supported by CIBER of Epidemiology and Public Health (CIBERESP)</section></section><section><section><h2>Authors contributions</h2>Ana Avellón designed the study and was the principal investigator of the study. Jorge Martinez-Laso developed the HLA study and interpreted its results. Isabel Cervera and Milagros Muñoz provided technical assistance. Inmaculada Casas was responsible of storage of total blood samples. Jorge Martinez-Laso and Ana Avellón wrote the manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>Authors declare no conflicts of interests</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":25.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-16DOI: 10.1016/S0168-8278(24)02531-5
{"title":"Register with early fees for the EASL SLD Summit 2025 by 1 November","authors":"","doi":"10.1016/S0168-8278(24)02531-5","DOIUrl":"10.1016/S0168-8278(24)02531-5","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：